Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

about

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

P2860

Q47133172-54E2781F-8547-4035-A3C0-66FCBC0925CB

P2860

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q47117016

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@en

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@nl

type

Item

label

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@en

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@nl

prefLabel

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@en

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@nl

P1476

Combined targeting of STAT3 an ...... e in chronic myeloid leukemia.

@en

P2093

Abbarna A Cumaraswamy

http://www.w3.org/2001/XMLSchema#string

Daniela Berger

http://www.w3.org/2001/XMLSchema#string

Gregor Hoermann

http://www.w3.org/2001/XMLSchema#string

Hiroshi Maeda

http://www.w3.org/2001/XMLSchema#string

Islam Waliul

http://www.w3.org/2001/XMLSchema#string

Karoline V Gleixner

http://www.w3.org/2001/XMLSchema#string

Katharina Blatt

http://www.w3.org/2001/XMLSchema#string

Konstantin Byrgazov

http://www.w3.org/2001/XMLSchema#string

Mathias Schneeweiss

http://www.w3.org/2001/XMLSchema#string

Michael Deininger

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Overriding imatinib resistance with a novel ABL kinase inhibitor

Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism.

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

P304

1519-1529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.163436

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28596283

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5685220

http://www.w3.org/2001/XMLSchema#string

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

about

P2860

P2860

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932